{"schema_version":"secwatch.filing_event.v1","accession":"0001447362-22-000171","form_type":"8-K","ticker":"CSTL","cik":"0001447362","company_name":"CASTLE BIOSCIENCES INC","filed_at":"2022-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.699504+00:00","generated_at":"2026-06-22T13:21:32.350497+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Castle Biosciences Q3 revenue $37M (+58% YoY), raises 2022 guidance to $132-137M","bullets":["Q3 revenue $37.0M (+58% YoY); total test reports 12,114 (+57% YoY).","Net loss $(20.2)M vs $(11.8)M; adjusted EBITDA $(8.3)M vs $(5.5)M.","2022 revenue guidance raised to $132-137M from $130-135M.","Three-year target: FY2025 revenue $255-330M; positive net operating cash flow by 2025.","Acquisitions TissueCypher (690 reports) and IDgenetix (1,208 reports) contributed in Q3."],"urls":{"canonical":"https://secwatch.observer/filing/0001447362-22-000171","json":"https://secwatch.observer/filing/0001447362-22-000171.json","markdown":"https://secwatch.observer/filing/0001447362-22-000171.md","text":"https://secwatch.observer/filing/0001447362-22-000171.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447362/000144736222000171/0001447362-22-000171-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447362/000144736222000171/cstl-20221102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T13:21:32.350497+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d298218479bed4ad57a105b530e4c9a3b799d63c","claim":"CASTLE BIOSCIENCES INC reported the third quarter ended September 30, 2022 results: revenue $37.0 million, net income $(20.2) million. Guidance raised.","evidence_excerpt":"Revenues were $37.0 million, a 58% increase compared to $23.5 million during the same period in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447362/000144736222000171/0001447362-22-000171-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$37.0 million"},{"label":"Net income","value":"$(20.2) million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"f0fc9b3f8abce0071ee20b7a348a506482c8efe7","claim":"CASTLE BIOSCIENCES INC reported the nine months ended September 30, 2022 results: revenue $98.7 million, net income $(46.5) million. Guidance raised.","evidence_excerpt":"Revenues were $98.7 million, a 43% increase compared to $69.0 million during the same period in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447362/000144736222000171/0001447362-22-000171-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the nine months ended September 30, 2022"},{"label":"Revenue","value":"$98.7 million"},{"label":"Net income","value":"$(46.5) million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}